What is Deepcell?
Deepcell operates at the intersection of advanced computational intelligence and life sciences. Founded in 2017, the company has developed a unique platform that utilizes continuously learning AI to analyze and sort cells based on detailed visual features. This capability is transformative for the field of single-cell analysis, as it allows for the isolation of rare cell types—even those occurring at frequencies as low as one in a billion—while maintaining cell viability for downstream applications. By removing inherent bias from the classification process, Deepcell is establishing a new standard for diagnostics and therapeutic discovery, effectively bridging the gap between raw biological data and actionable clinical insights.
How much funding has Deepcell raised?
Deepcell has raised a total of $93M across 2 funding rounds:
Series A
$20M
Series B
$73M
Series A (2020): $20M with participation from Stanford University, 50Y, DCVC, Andreessen Horowitz, Jeff Dean, and Bow Capital
Series B (2022): $73M led by Bridger Healthcare, Casdin Capital, Koch Disruptive Technologies, and Horizons Ventures
Key Investors in Deepcell
DCVC
DCVC is a deep tech venture capital firm that invests in entrepreneurs tackling some of the world's most challenging problems, with a specific focus on leveraging artificial intelligence to unlock potential in biotechnology.
Casdin Capital
Casdin Capital brings deep expertise and a long-term perspective to financing the next generation of life science innovation, particularly within the diagnostics and molecular information sectors.
Bow Capital
Bow Capital is a venture capital fund that connects academia, business, and technology, specializing in guiding startups to become multibillion-dollar businesses through a vast network of industry leaders.
What's next for Deepcell?
With the support of its latest capital infusion, Deepcell is poised to transition its technology from a specialized service model to a broader commercial application. The strategic focus will likely center on expanding the utility of its platform within the diagnostics and therapeutic development sectors. As the company continues to refine its AI algorithms, the ability to deliver unprecedented views of cell biology will be critical in addressing complex medical challenges. Future growth will depend on the firm's ability to integrate its high-throughput sorting capabilities into existing clinical workflows, thereby cementing its role as a foundational player in the next generation of precision medicine infrastructure.
See full Deepcell company page
